Logo image of ZVRA

ZEVRA THERAPEUTICS INC (ZVRA) Stock Fundamental Analysis

NASDAQ:ZVRA - Nasdaq - US4884452065 - Common Stock - Currency: USD

9.15  +0.15 (+1.67%)

After market: 9.15 0 (0%)

Fundamental Rating

3

ZVRA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. ZVRA may be in some trouble as it scores bad on both profitability and health. ZVRA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZVRA had negative earnings in the past year.
In the past year ZVRA has reported a negative cash flow from operations.
In the past 5 years ZVRA always reported negative net income.
In the past 5 years ZVRA reported 4 times negative operating cash flow.
ZVRA Yearly Net Income VS EBIT VS OCF VS FCFZVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -53.26%, ZVRA is doing worse than 62.56% of the companies in the same industry.
With a Return On Equity value of -224.24%, ZVRA is not doing good in the industry: 71.28% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -53.26%
ROE -224.24%
ROIC N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVRA Yearly ROA, ROE, ROICZVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

Looking at the Gross Margin, with a value of 84.42%, ZVRA belongs to the top of the industry, outperforming 90.77% of the companies in the same industry.
ZVRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVRA Yearly Profit, Operating, Gross MarginsZVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZVRA has more shares outstanding than it did 1 year ago.
ZVRA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ZVRA has a worse debt to assets ratio.
ZVRA Yearly Shares OutstandingZVRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ZVRA Yearly Total Debt VS Total AssetsZVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.64, we must say that ZVRA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.64, ZVRA is in line with its industry, outperforming 47.18% of the companies in the same industry.
A Debt/Equity ratio of 1.46 is on the high side and indicates that ZVRA has dependencies on debt financing.
With a Debt to Equity ratio value of 1.46, ZVRA is not doing good in the industry: 75.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Altman-Z -2.64
ROIC/WACCN/A
WACC10%
ZVRA Yearly LT Debt VS Equity VS FCFZVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.02 indicates that ZVRA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.02, ZVRA is in line with its industry, outperforming 52.82% of the companies in the same industry.
A Quick Ratio of 2.93 indicates that ZVRA has no problem at all paying its short term obligations.
ZVRA has a Quick ratio (2.93) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.93
ZVRA Yearly Current Assets VS Current LiabilitesZVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

ZVRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.22%.
ZVRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.90%.
ZVRA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.96% yearly.
EPS 1Y (TTM)-42.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85%
Revenue 1Y (TTM)44.9%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%495.65%

3.2 Future

The Earnings Per Share is expected to grow by 28.22% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 78.42% on average over the next years. This is a very strong growth
EPS Next Y139.93%
EPS Next 2Y49.59%
EPS Next 3Y39.32%
EPS Next 5Y28.22%
Revenue Next Year342.69%
Revenue Next 2Y181.22%
Revenue Next 3Y127.91%
Revenue Next 5Y78.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZVRA Yearly Revenue VS EstimatesZVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ZVRA Yearly EPS VS EstimatesZVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80 -100

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

ZVRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 17.03, ZVRA is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ZVRA is valued a bit cheaper than the industry average as 76.41% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.27. ZVRA is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 17.03
ZVRA Price Earnings VS Forward Price EarningsZVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVRA Per share dataZVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ZVRA's earnings are expected to grow with 39.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.59%
EPS Next 3Y39.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZVRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZEVRA THERAPEUTICS INC

NASDAQ:ZVRA (6/24/2025, 4:30:02 PM)

After market: 9.15 0 (0%)

9.15

+0.15 (+1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners63.45%
Inst Owner ChangeN/A
Ins Owners0.62%
Ins Owner Change54.89%
Market Cap500.32M
Analysts84.29
Price Target22.88 (150.05%)
Short Float %10.65%
Short Ratio9.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.57%
Min EPS beat(2)-67.34%
Max EPS beat(2)68.49%
EPS beat(4)1
Avg EPS beat(4)-16.97%
Min EPS beat(4)-67.34%
Max EPS beat(4)68.49%
EPS beat(8)3
Avg EPS beat(8)-8.84%
EPS beat(12)3
Avg EPS beat(12)-21.64%
EPS beat(16)5
Avg EPS beat(16)-14.2%
Revenue beat(2)2
Avg Revenue beat(2)25.11%
Min Revenue beat(2)17.95%
Max Revenue beat(2)32.28%
Revenue beat(4)3
Avg Revenue beat(4)6.19%
Min Revenue beat(4)-25.59%
Max Revenue beat(4)32.28%
Revenue beat(8)5
Avg Revenue beat(8)22.76%
Revenue beat(12)6
Avg Revenue beat(12)9.85%
Revenue beat(16)8
Avg Revenue beat(16)9%
PT rev (1m)0.64%
PT rev (3m)0.64%
EPS NQ rev (1m)1.25%
EPS NQ rev (3m)729.7%
EPS NY rev (1m)33.8%
EPS NY rev (3m)364.24%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)3.07%
Revenue NY rev (1m)4.13%
Revenue NY rev (3m)2.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.03
P/S 12.33
P/FCF N/A
P/OCF N/A
P/B 12.2
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)0.54
Fwd EY5.87%
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.74
BVpS0.75
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.26%
ROE -224.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.42%
FCFM N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 94.18%
Cap/Sales 15.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.02
Quick Ratio 2.93
Altman-Z -2.64
F-Score3
WACC10%
ROIC/WACCN/A
Cap/Depr(3y)44.3%
Cap/Depr(5y)36.5%
Cap/Sales(3y)9.12%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85%
EPS Next Y139.93%
EPS Next 2Y49.59%
EPS Next 3Y39.32%
EPS Next 5Y28.22%
Revenue 1Y (TTM)44.9%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%495.65%
Revenue Next Year342.69%
Revenue Next 2Y181.22%
Revenue Next 3Y127.91%
Revenue Next 5Y78.42%
EBIT growth 1Y-26.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.79%
EBIT Next 3Y40.08%
EBIT Next 5Y32.81%
FCF growth 1Y-251.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-221.13%
OCF growth 3YN/A
OCF growth 5YN/A